Pharmaceuticals, Biotechnology and Life Sciences
The LYRICA Pediatric Epilepsy Program is composed of six studies in
patients with epilepsy evaluating LYRICA as adjunctive therapy, five of
which have been completed.
Medicure Inc reported net loss for the quarter ended March 31, 2019 at $2.8 million compared to net income of $1.4 million for the quarter ended March 31, 2018.
Jakafi is the first and only FDA-approved treatment for patients with
steroid-refractory acute graft-versus-host disease (GVHD)
PHILADELPHIA–(BUSINESS WIRE)–Wharton Research Data Services (WRDS), the leading data research platform and business intelligence tool for corporate, academic and government…
DUBLIN–(BUSINESS WIRE)–The “Orphan Drugs – Market Analysis, Trends, and Forecasts” report has been added to ResearchAndMarkets.com’s offering. The report provides…
LONDON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Biotechnology?src=hash" target="_blank"gt;#Biotechnologylt;/agt;–Technavio’s latest market research report on the global biosimulation market predicts the market to witness a CAGR…
LONDON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Biotechnology?src=hash" target="_blank"gt;#Biotechnologylt;/agt;–The global gene therapy for inherited genetic disorders market is expected to post a CAGR of about…
DUBLIN–(BUSINESS WIRE)–The “Global Hearing Implant Market – Analysis By Type (Cochlear Implant, Bone Anchored Hearing Aid, Acoustic Brainstem Implant, Middle…
DUBLIN–(BUSINESS WIRE)–The “Global Biopharmaceutical CMO Market – Analysis By Region, By Country: Opportunities and Forecast (2018-2023) — By Region (North…
PARSIPPANY, N.J. & JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceuticals USA and related affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and…